

Prescription Drug Technical Advisory Group

September 20, 2022



Overview of Advisory Group



- The Board's Prescription Drug Advisory Group was established in 2020 to examine potential state solutions to help curb the rising costs of prescription drugs.
 - December 2020
 - Convened the first public meeting
 - Spring 2021 through Spring 2022
 - Subgroups convened, occasionally sharing recommendations/updates
 - Summer 2022
 - Subgroups adjourned
 - Fall 2022
 - Regroup to determine future work, if any

**Meeting information and membership may be found on the GMCB Prescription Drug Technical Advisory Group's webpage [here](#).*

Group Priorities

1. Out-of-pocket costs (24 points)
 2. PBM regulation/issues (21 points)
 - Rebate and/or price transparency
 3. Formulary management for high-cost and specialty drugs (18 points)
 4. Bulk/group purchasing (16 points)
 - Increase transparency; review board; reference pricing; regional/group risk pool
 5. Pharmacy access and sustainability in Vermont (11 points)
- Previously convened subgroups on these topics

Related Legislation

- Legislation passed in 2022
 - [Act 131 \(H.353\) – An act relating to pharmacy benefit management](#)
- Legislation not passed in 2022
 - [S.243 - An act relating to implementation of an unused prescription drug repository program](#)
 - The Vermont Department of Health testified they did not need a bill to pursue the feasibility analysis and assured the legislature its intent to perform the research with or without legislation.
 - [S.193 – An act relating to strategies for reducing prescription drug costs for Vermonters](#)

Future Group Work

Discussion Questions

1. Should the group continue or sunset at this time?
2. If yes, what issues should the group focus on moving forward?
 - Current priorities: affordability, PBM regulation/issues, formulary management for high-cost & specialty drugs, bulk/group purchasing, and pharmacy access & sustainability
3. If yes, are there other issues the group would like to prioritize?